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Abstract 
Research on an Artificial Pancreas has gained its 
momentum and focused on the processing of clinical 
data for continuous insulin administration. However, 
the overall research is rather sketchy, fragmented and 
not very well coordinated.  In this paper, we propose 
an architectural model for creating software intensive 
environments, which address deficiencies of current 
solutions for insulin infusion.  A new way of defining 
which data should be collected and which types of 
computations should be performed with the data is 
important if we wish to come close to the functioning 
of a natural pancreas.  An excerpt of the proposed 
software architecture has been deployed using Watson 
Analytics and performed upon a selection of data 
collected from sensors, individual patient’s input and 
persistent patient records. 
1. Introduction  
According to the Norwegian "National Diabetes 
Plan 2017-2020" [16] there are approximately 245 000 
persons diagnosed with diabetes in Norway, of whom 
28 000 have DMT1. Each year there are another 300 
children (age <15 years) diagnosed with DMT1. In 
Norway, the annual increase in number of newly 
diagnosed diabetics is less pronounced, though the 
total number of persons living with diabetes (DM) 
continues to grow. In 2014, the World Health 
Organization reported that there was an estimated 
worldwide number of 422 million adults living with 
DM [31], and the estimated total monetary cost of 
diabetes is more than 827 billion USD per annum. 
DM is a chronic non-communicable disease that 
causes the patient pancreas to stop producing insulin 
[1]. As an autoimmune response to some unknown 
factor: the beta-cells of the pancreas are destroyed and 
ultimately unable to produce enough, if any, insulin. If 
left untreated, the Blood Glucose (BG) levels continue 
to increase, the metabolic processes deteriorate, and 
the patient shows symptoms of hyperglycaemia, which 
may cause coma and/or death [14, 22]. During the last 
30 years there has been tremendous progress in the 
research and development of technological aids for 
diabetes management.   Today, we talk about hybrid 
closed-loop system, which sense a patient’s BG level, 
calculate and administer a basal, or bolus, dose of 
insulin. They consist of a BG measuring device, a 
continuous glucose-monitoring unit (a control unit), 
and an insulin infusion unit. Open-loop insulin 
infusion systems are different because the control unit, 
often placed within the insulin infusion device, is 
dependent on the patient manual input to calculate an 
insulin dose. The patient must approve the dose or 
adjust it according to their own calculations. An 
Artificial Pancreas (AP), which is expected to be a 
closed-loop system, aims to perform these tasks with 
little or no manual user input. 
In this paper, we analyse research ideas for the 
development of an AP and systemise problems found 
in the relevant literature.  We propose a new way of 
looking at the development of an AP by revisiting data 
sets and computations found in current insulin 
administrations.  The outcome is interesting.  The data 
sets currently processed in open/closed loop insulin 
infusion systems, are not sufficiently rich and broad to 
be compared with the data our natural pancreas uses in 
insulin administration.  Furthermore, the processing of 
the data appears to be insulin pump manufacturer 
specific and does not allow for variations in the way 
we collect and process data.  Therefore, we advocate 
changes in both: data types we collect and the type of 
computations we can perform upon the data.   
The paper is organized as follows. In section 2 we 
overview a selection of research papers which either 
influenced our research or address some of the aspects 
of insulin administration, which could mimic the 
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functioning of a natural pancreas. Section 3 itemises 
problems we detected in the literature, which focuses 
on various aspects of creating an AP.  In section 4 we 
analyse additional problems which appear within 
current insulin administration systems and in Section 
5 we offer our proposal which addresses these 
problems.  The proposal consists of (i) a new data 
model and (ii) a software architecture, for creating a 
software intensive environment for insulin 
administration.   We expect that the solution would 
closely mimic the functionality of a natural pancreas.  
In section 6 we conclude by outlining what the next 
step in the development of an AP could be. 
2. Related Work 
2.1. Evolution of Insulin Administration 
The administration of insulin entails a basal rate, to 
ensure the constant presence of insulin [8], and a bolus 
amount injected.  It compensates for spikes in BG 
levels, due to food intake or unexpected hyper-
glycaemia [6]. During the last 30 years, this process 
changed from an analogue procedure to using 
increasingly advanced technologies.  In 2004, 
Siebenhofer et al [21] performed a meta-analysis of 27 
randomized control trials to compare the effect of 
treating DMT1 patients either with short-acting insulin 
analogues or with regular insulin (non-analogue). The 
treatments were administered through continuous 
subcutaneous insulin infusion (CSII) or as intensified 
insulin therapy (IIT). The results suggest that the rate 
of hypo-glycemic episodes was NOT reduced by using 
analogues (compared with non-analogue), but the CSII 
therapy provides a small, yet statistically significant, 
improvement in glycemic control compared to that of 
IIT. In 2011 Wang et al [30] describe the "glucose-
meal-insulin dynamics" as a "traditional batch 
process” and explain how run-to-run (R2R) algorithms 
are used to calculate the bolus amount of insulin to 
administer. By 2014, we had a complete and well 
written description of what AP is in [19] and in 2015, 
Barnard et al [3] have performed a systematic review 
of available research on the psychosocial and 
psychological measures suitable for use in the research 
of future AP's. They found very little evidence that 
research, related to AP, includes these measures.   
2.2. Open-Loop Systems   
In addition to using the improved "basic" Blood 
Glucose Measuring (BGM) devices, patients can now 
track their interstitial glucose levels using a 
Continuous Glucose Monitoring (CGM) device. 
Current state of art includes features that enable both 
devices to connect to and/or transmit the 
measurements to an insulin pump. The pump sends 
these inputs to some pre-programmed algorithms and 
advises the patient to adjust their insulin delivery. It 
may suggest a calculated insulin dose or even provide 
an alarm if the BG level is outside, or nearing, a pre-
set safe range of glucose concentration [15]. The 
patient must, however, always perform their own 
calculation and adjust or administer a dose according 
to their own individual experience and knowledge 
[29]. The current open-loop systems are dependent on 
these inputs, to ensure safe and reliable dosages being 
infused with the correct time interval [6].  
2.3. Closed-Loop Insulin Infusion Systems  
Closed-loop systems are often termed as an AP. 
[26]. The authors claim that the end goal is to create a 
real-time embedded system that requires little to no 
management from the patient, yet function at the 
highest level of accuracy, safety and reliability [14-
16].  They usually consist of three units: a glucose 
monitoring unit, an insulin infusion unit and a control 
unit [7]. The AP could, however, also include the 
infusion of glucagon, to compensate for decreasing 
BG in the way a real pancreas would [9].  
2.4. Closing the Loop with Algorithms 
Historically, research has focused on creating 
devices for either glucose monitoring or insulin 
infusion [7]. To create and close the loop, the control 
unit contains algorithms within the insulin infusion 
device, or sometimes becomes a part of a separate 
control device managed by the user/patient [7, 27, 28, 
32]. The algorithms use collected data (i.e. BG) as an 
input to calculate a dose of insulin, to be administered 
through the insulin infusion unit.  
One of the frequently mentioned algorithm form 
[30] is based on Model-Predictive-Control (MPC) and 
Iterative Learning Control (ILC) to perform glycaemic 
control.  It does not require user intervention and might 
be applicable to children and adolescents.  The 
Turksoy et al form [27] present a different approach: 
they created a multimodule AP system, which includes 
adaptive algorithms for handling unexpected changes 
in physiological variables received from wearable 
devices. Therefore, they note that exercise may affect 
BG concentrations.  The algorithm from [28], used for 
meal-detection, is based on CGM measurements and 
predicts almost all tested meals in their experiments.  
Toffanin et al [25] propose an adaptive MPC 
algorithm based on an R2R approach, to potentially 
"capture intra- and inter-day glucose variability…". It 
uses the data from a CGM and calculates a basal dose 
during night and a "carbohydrate-to-insulin ratio" 
(CR) in the day.  Boiroux et al [6] propose a method 
to track the postprandial glucose dynamics and insulin 
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sensitivity. Using a virtual model, they created a 
calculator for basal and bolus doses. It is dependent on 
patients entering their meals to calculate the correct 
bolus dose. They used a switching strategy between 
meal and insulin sensitivity estimation to allow for 
tracking the correct insulin sensitivity. 
Samadi et al [20] showed the algorithm for 
detecting meals and estimating their size in the form 
of carbohydrate amount.  It is based on “the 
interpretation of qualitative representation of CGM 
signals" and integrates wavelet filter, qualitative 
representation and fuzzy logic.  
The algorithm from Ortmann et al [17], is based on 
MPC and considers periodic insulin sensitivity (IS), 
which changes with a patient's circadian rhythm, to 
improve BG control. They use machine learning (ML) 
to predict the effect of the IS.  Bamgbose et al [2] 
propose a simulation framework, also based on ML 
techniques, for an integrated control system of 
administering bolus. The predictive controller uses the 
patient's medical records for its calculations.   The only 
clinical data processed are insulin and BG levels.  
Keith-Hynes et al [12] propose a "Diabetes 
Assistant" (DiAs) as an AP research platform. They 
perform clinical studies of AP's on portable devices 
and smartphones. It will be interesting to see if their 
ideas materialise.  Lazaro et al [13] propose a closed-
loop AP system implemented on a mobile device by 
integrating an insulin pump, a GCM, and other 
sensors, with various software components, which 
should have a common goal of controlling BG levels.  
It is important to note that there are safety 
implications, issues of data accuracy and the reliability 
of data input via user interface [5].  The increased risk 
of life-threatening complications for those living with 
DMT1, must be considered when developing an AP 
which assumes the roles of a human organ.  
3. The Problem 
The development of an embedded real-time 
system, which mimics the biological functions of a 
human organ, has many challenges. Current research 
on an AP seems to be fragmented and scattered around 
various devices and software embedded within them.  
Although each of them contributes towards an AP, this 
fragmentation makes it difficult to discover 
(a) where and how to streamline further 
improvements in the development of an AP; 
(b) where the obstacles of developing a full-scale 
AP actually lie; 
(c) if we could create a software intensive 
solution which replaces the functioning of our 
natural organ”. 
In trying to address (a)-(c) we summarise problems 
from the literature into P1-P5.  
Problem P1: Which clinical data should be 
collected and manipulated? 
There is no consensus in AP research which 
answers problem P1. Control units depend on clinical 
measurements as input for their control algorithms.  
Manufacturers of these devices claim that they focus 
on the data, which ensure “correct insulin 
administration”.  Has anyone analysed the full scale 
of data spectrum used in the functioning of a natural 
organ? Do current solutions for AP take them all into 
account? In just one simple example, where the 
glucose concentration of interstitial fluid of the 
subcutaneous tissue, is juxtaposed to glucose 
concentration of the intravenous blood, we do not have 
equal values.  Do CGM devices compensate for that 
lag? We found devices that may be placed intra 
peritoneum, to achieve direct access to blood glucose, 
but how likely is it that this will become a mainstream 
solution for an AP?   
Problem P2: Which non-clinical data could be 
relevant for creating an AP? 
The human body and our metabolism are affected 
by many factors. When calculating an insulin dosage, 
non-clinical data may prove to be valuable data inputs. 
These include subjective/personal data, environmental 
conditions, ambient temperature, psychosomatic 
issues and the body's ability to process food.  No 
published work exists which considers these factors as 
part of a “holistic algorithm” for controlling insulin 
infusion. 
Problem P3: How does the Insulin Sensitivity 
Factor affect the functioning of an AP? 
Insulin sensitivity (IS) is the definition of how 
quickly and easily the body reacts to the effects of 
insulin (both endo- and exogenous). As an AP may 
include continuous monitoring of BG, we question if 
this factor is needed as an input for the algorithms, or 
will it become redundant for an AP? 
Problem P4: How would Active Insulin affect 
bolus algorithms in an AP? 
We assume that an AP will work by continuously 
administering small, well-calculated, doses of insulin, 
without inputs from the user. Will it therefore need to 
compensate for this active insulin according to its own 
calculations? 
Problem P5.1 – Current data processing and 
control algorithms do not address most of the 
problems from P1-P4 and should be revisited.  
The data in the current AP solutions is very often 
processed by devices, which collect them and 
administer insulin.  The algorithms are embedded 
within devices, but in the era of Big Data technologies, 
embedding software solutions into devices does not 
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look promising. An AP needs continuous 
computations, which cannot be hindered by the pre-
processed data with embedded software.  Would 
embedded software allow changes in the way AP data 
is collected and processed?  
Problem P5.2 – Should AP enable a greater 
patient centric treatment regime? 
The problem of computing a correct insulin 
treatment regime should be resolved at the patient 
level and should not be dependent on a) scheduled 
visits to a specialized healthcare professional and b) 
rules prescribed by the embedded software in AP 
devices. An AP should work autonomously and 
independently, by providing patients with advice and 
warnings, for adjustments to the treatment regime.  
Could we achieve this through our computations? 
4. Example of Insulin Administration 
Before we try to address problems P1-P5 we 
analyse one of the hybrid insulin administration 
systems available in Norway [2]. Figure 1 is a general 
visualization of such an infusion system.   
The CGM device (1) is attached with a small 
sensor needle placed in the subcutaneous tissue. This 
measures the glucose concentration every 5 minutes 
and transfers the results to the control unit within the 
insulin infusion device (2). The control unit is the most 
advanced of the sub-systems and contains settings and 
algorithms which define the functionality of the entire 
system. Upon receiving the sensory data, the control 
unit performs various calculations and provides 
auditory and visual warnings, when necessary. This is 
the unit which controls and monitors the infusion of 
insulin through the infusion site (3). Being an open-
loop system means that all functions within the control 
unit rely on settings and inputs provided by the user.   
The "Medtronic CareLink Personal" is a web 
application which allows uploading the insulin 
administration data and generating reports from their 
clinical diabetes related data.  These reports are very 
detailed, and patients need a certain degree of 
technical and analytical skills to understand them. The 
grouped reports are detailed and cluttered, which 
makes them difficult to interpret. The single reports 
consist of the same six columns, regardless of which 
report is selected, and are useful only when searching 
for very specific data and results.   
We ran reports on progress and BG trends, glucose 
measurements correlated to meals, insulin calculations 
and administrations and glucose measurements and 
flagged events.  However, our interest was in the data 
set generated by this hybrid open loop system, which 
was downloadable as a .csv-file via the web-
application and viewed by MS Office Excel.  Column 
headings of datatypes collected by the control unit are 
BWZ of calculation (E), goal high BG (mmol/L), goal 
low BG (mmol/), carbohydrate data input (gram) 
BWZ BG data input (mmol/L), BWZ correctional 
calculation (E) and food calculation (E), where BWZ 
stands for Bolus Wizard Data.  There are also 
numerous data setting which cannot be discussed due 
to space limitation. 
4.1. Manual Analysis of the Dataset  
The manual analysis of the data set revealed 
interesting results. The structure of the spreadsheet 
and its columns explains the meaning of the data 
within it.  However, the spreadsheet contains both raw 
and processed data, and it remained unknown to us 
how that data was processed. It was obvious that prior 
computation must have been performed on some of the 
data, as they contain attributes as well as values.  
Therefore, the data have different levels of values, 
which automatically signalled that we might not be 
able to perform further processing of the dataset. This 
becomes an obstacle in performing any other 
analytical tasks, except for the ones already 
determined by the manufacturer of the control unit.  
This is clearly a proprietary solution, set to work in 
restricted environments, and by only a selected 
number of stakeholders and users. It is not a reusable, 
nor available model for data collection or different 
processing and decision making we may need in 
future.  This was an unexpected disappointment: this 
relatively widely used software solution in Norway, is 
probably outdated in today's climate of increasingly 
advanced data processing technology, particularly in 
Big Data environments.  
4.2. Applying WA to the Dataset 
Our initial idea of using the Big Data technologies 
upon sensory generated data, which could help in 
insulin administration, was tested by applying Watson 
Analytics (WA) on this dataset. We faced numerous 
problems: our data set was of only 9% quality, vetted 
by WA; column headers interpreted by WA made no 
sense; several columns related to the time stamps 
appeared, and the discovery set defined by WA was 
 
Figure 1 - Open-Looped or Hybrid Insulin 
Administration System 
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impossible to interpret.  The most predominant value 
in our data set found by WA was BLANK.  Obviously, 
we could not process the data set by WA.  
Though we expect WA to accept an untouched 
dataset, and enable us to run analysis directly, this was 
not the case.  Most of the columns contained 
Norwegian words, which were changed to 
unrecognizable and highly unsuitable names, making 
it impossible to create sensible discovery sets. Though 
the set was quite large (over 13.000 rows) many of the 
cells were empty, decreasing the quality score. The 
fact that the so-called "raw data" is already semi-
processed and stored as values within one single 
column of the original file, seem to "confuse" WA, 
which makes analysis even more troublesome. 
5. The Proposal 
Section 3 and 4 highlighted that we have to address 
two important problems when developing an AP.  
The first focuses on the creation of a new data 
model, which would address P1-P4 from section 3 and 
would be sufficient for performing computations, 
which mimic functionalities of a natural pancreas.  We 
found no publications, which explore the world of the 
natural pancreas first and then mirror it to the world of 
data collection from our body.  It is not sufficient to 
base calculations for insulin administration solely on 
BG and SG readings and a small selection of clinical 
data closely related to glucose/insulin levels and the 
food patients consume. 
The second focuses on P5.1 and P5.2. and the 
choices of insulin infusion devices. They process 
collected data, but the processing is proprietary of the 
device’s manufacturer(s).  This makes any changes to 
the data devices collect and process, impossible. 
Sensors around our bodies would generate an 
excessive amount of data, and their processing with 
Big Data technologies might be inevitable in the 
modelling of the functionality of an AP.  In the current 
climate, the data we collect, and have access to, are not 
suitable for further processing, except within software 
solutions provided by device manufacturers. 
Therefore, we propose: 
a) A new data model for creating computations 
for an AP and addressing P1-P4; 
b) A Software Architectural model, which uses 
the data from a) and addresses P5.1 and P5.2.; 
c) An excerpt of the implementation of our 
Software Architectural model from b) with IBM WA.  
This can build a long-term strategy of personalized 
insulin administration by patients.  
 
5.1. Data Model for an AP 
Table 1 shows the proposed data model from a). 
The left column contains known Diabetic Specific 
Clinical Data, which we expect to be either collected 
or calculated.  Some of the data from this column are 
settings for enabling AP calculations, which could 
either be prescribed in advance, or dynamically 
changed by the patient and/or AP.  The middle column 
in Table 1 contains clinical data which may influence 
the administration of insulin but are not directly 
related to BG measurements. The right column 
contains patient personal/ subjective data which 
characterises the environment of an individual patient.  
These three distinctive columns are not created by 
accident.  The data from the left column are mostly 
present in insulin infusion systems based on devices, 
which collect, and process sensor generated data (BG 
and SG).  The data from the middle column are chosen 
to add more semantics to diabetes specific clinical 
data: because they might affect insulin secretion. The 
data from the right column are personalised 
observations, feelings and perceptions patients may 
have about themselves, which may also affect the way 
insulin is administered.  Each column contains data 
collected and processed differently, but the data across 
columns are interwoven and influence each other even 
outside these column barriers.  In current commercial 
solutions of insulin infusions, only data from the left 
column are used and the semantics stored in the middle 
and right column are largely ignored.  
The rationale behind and description of the data 
model from Table 1 are given in the paragraphs below. 
Table 1 – The proposed data model 
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BG versus SG. The best approach to insulin 
infusion would be to directly measure BG with  
intravenous implantable devices to avoid wrong 
calculations of BG from SG readings.  Unfortunately, 
only subcutaneous and microdialysis studies have 
yielded commercial products.  All sensors are enzyme-
based and boronic acid derivatives, as enzyme-free-
based assays, might not be in clinical use.  Also, 
environment temperature and pH of intestinal fluids 
can lead to wrong readings of SG and consequently to 
wrong calculations of BG.  Furthermore, there is a 
delay between BG and SG changes, which can be 
between 5 and 15 min, and thus life-threatening, 
because the patient could already be in hypoglycaemia 
with still normal SG readings.  One would think that if 
BG measurements cannot be achieved instantly, then 
we should set alerts for the high and low SG levels.  
However, they must be highly personalized.  We have 
to measure BG (with prick test) and SG (with sensor) 
at the same time and define/set their relationship for 
each patient individually.  Obviously, in a fully 
functioning AP these relationships are prerequisites, if 
we still wish to use SG levels in BG calculations. 
Insulin Sensitivity and Insulin Correction 
Factors.  The Insulin sensitivity factor is the drop in 
BG level caused by each unit of insulin administered.  
For this factor BG levels are in mg/dL and it can be 
calculated by dividing 1800 (rapid insulin) with the 
number of daily doses of insulin.  Situations that cause 
the insulin to carb ratio to rise will cause the insulin 
sensitivity factor to drop, i.e. the insulin to carb ratio 
will rise because of the drop of insulin sensitivity and 
thus the insulin correction factor is calculated 
similarly: 100 / TDD (total daily doses) in mmol/L.  
Obviously, these two factors are heavily interwoven. 
Insulin Sensitivity and Insulin to Carb Ratio. 
Further analysis of insulin sensitivity factors takes us 
to insulin to carb ratio.  We have to collect a new set 
of data if we wish to mimic the functioning of a natural 
pancreas.  The data from the second and third column 
in Table 1 are created from 1) – 7) below. This is very 
important, because the calculations of insulin to carb 
ratios vary and depend on other types of data not 
identified in the left column in Table 1. 
1) The insulin to carb ratio should be higher in 
the mornings because of the Down Phenomena.  Our 
body produces more hormones (growth hormone, 
cortisol and adrenalin) that trigger the liver to 
metabolize glycogen to glucose and pump it into the 
blood. 
2) When hypoglycemia occurs during the night, 
due to the Somogyi Effect, our body goes into panic 
mode and secretes hormones like glucagon and 
adrenaline, which does the same: trigger the liver to 
metabolize glycogen into glucose and pump it into the 
blood. 
3) The insulin to carb ratio changes during the 
menstrual cycle. In the follicular phase insulin 
sensitivity increases because of increased FSH levels 
and thus the insulin to carb ratio should be lower. In 
the early luteal phase insulin sensitivity decreases 
because of the increase of progesterone levels and the 
insulin to carb ratio should be higher.  The use of 
hormone-based contraceptives also affects the insulin 
to carb ratio.  
4) During illness (especially viruses) sensitivity 
to insulin is lower and the insulin to carb ratio should 
be higher. 
5) Stressful situations (with high cortisol levels) 
require increasing the insulin to carb ratio. Cortisol 
causes decreased insulin sensitivity and triggers the 
liver to release more glucose into the blood.  
6) The insulin to carb ratio should be lower 
during exercise and when we are in the honeymoon 
mode because (i) the sensitivity to insulin is higher and 
(ii) muscles can uptake glucose without insulin during 
contraction. 
7) Body fat changes the insulin to carb ratio: the 
more fat the higher insulin to carb ratio should be.  We 
should measure the amount of fat and muscles because 
the insulin to carb ratio will not necessarily be the 
same for the same weight of person.  
Insulin Sensitivity, Psychological Factors and 
Neurotransmitters.  It is important to note that insulin 
to carb and insulin sensitivity factor variations, 
affected by psychology state, exercise, fear, happiness 
and similar could be “detected” either by patient 
subjective feelings or by measuring levels of different 
hormones and neurotransmitters. The data from the 
middle and right columns cannot be avoided and their 
presence is further justified in a-d.: 
a. Acute stress must be measured through 
adrenalin levels, but as of today, it is still not possible 
to get continuous measurement of adrenalin. Chronic 
stress should be measured by cortisol levels, although 
if the person is exposed to stress for a very long time, 
cortisol levels can be low due to adrenal fatigue.  
Continuous measurement of cortisol is done by 
subcutaneous microdialysis [4] and research on AP 
should address it.  
b. Serotonin influences and is influenced by 
insulin release.  It stimulates the liver to produce more 
glucose. Antidepressants, which mostly work on the 
principle that they change serotonin levels, also affect 
insulin secretion. A rise in serotonin may be the key 
why we need less insulin when we are in the 
honeymoon mood. [18] states, that a lack of serotonin 
in the pancreas causes diabetes. Serotonin does raise 
blood glucose levels, because it forces the liver to 
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produce more sugar, but this effect is stronger than 
stimulation of insulin secretion. 
c. The neurotransmitter dopamine raises 
glucose: it stimulates the liver to pump glucose into 
the blood.  
d. Gut biota shows that mice with sterile guts 
are more prone to diabetes and therefore we should 
look at the role it may have in the creation of AP. 
To summarise, the content of Table 1 shows a 
minimum number of data to be collected if we wish to 
create computations, which mimic the functionality of 
a natural pancreas.  They may be measured through 
sensors, calculated upon their readings, entered by 
patients and doctors, and retrieved from any 
persistence, including patient healthcare data.  
Explanations on how to collect the data and perform 
calculations, is outside the scope of this paper. 
5.2. Software Architectural Model  
Figure 2 places the proposed data model, from the 
previous section, within the scenario in which data 
processing is carried out according to functionalities 
typical of a natural pancreas. Therefore, patient 
medical, and/or clinical and/or healthcare records 
(EMR/HER) are being manipulated and supported by 
the content of the APData model.  The semantics, 
behind the data placed in Table 1 should be 
manipulated through the reasoning upon SWRL 
enabled OWL ontologies.  Glucose drivers and trends 
could be obtained at any time from the APData, using 
WA. However, these three computations indicated in 
Figure 2 do not exist in isolation. They are interwoven 
because they share all data repositories and use the 
semantics stored in them, as a natural pancreas would 
do.  The idea of manipulating the data model from 
Table 1, illustrated in Figure 2 is transformed into the 
software architectural model in Figure 3, which 
generates a Software Application for an AP. 
Figure 3 shows software architectural components 
which enable computations upon the data model from 
Table 1, which could mimic functionalities of a natural 
pancreas.  The bottom set of software components are 
different types of data storage to enable these 
computations.  We can run WA upon the APData, 
manage persistent clinical data and patient healthcare 
records and reason upon the semantics we store in the 
data model from Table 1 in OWL ontology. Three 
different software technologies are used:  
a) WA for creating predictions and finding 
trends upon the patient’s management of BG; 
b) Transactional processing with the support of 
SQL, for performing calculations for insulin infusion, 
and updating persistent data and EMR;  
c) Semantic Web Technologies for performing 
reasoning upon SWRL enabled OWL ontologies for 
defining and manipulating the correlation between and 
meaning of data stored in APData/ Table 1.  
 
Figure 2 – The Scenario for the 
Proposed Data Model 
 
Figure 3 - Software Architectural 
Model 
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Software applications generated from Figure 3 can 
be deployed across various component based 
integrated development environments and Android 
(53).  We can process data with traditional 
transactional processing and reasoning upon OWL 
ontologies in parallel [11, 23, 24] and run the analytics 
by WA upon APData.  Detailed computations for the 
Data Management and Reasoning parts of Figure 3 are 
outside the scope of this paper but can be found in our 
earlier publications [10, 23]. 
The semantic overlapping between data described 
in Table 1 is managed by OWL concepts.  The result 
of reasoning with SWRL upon OWL will influence 
calculations of insulin infusion and result in updating 
persistent data, including APData, if necessary.  
Therefore, Figure 3 has multiple roles: (a) It shows 
architectural components which must be deployed to 
mimic the functionalities of an AP and (b) it defines 
variations in types of computations with data sharing 
amongst them.  Sensors, which collect data, could not 
be shown in any software architectural model, but the 
data they generate have their place in sections of the 
APData model from Table 1.  Sensors we will use in 
future should only collect data, which means that the 
architecture from Figure 3 is not insulin infusion 
device specific.  
5.3 Running WA upon APData 
Our APData content was created according to the 
data model from Table 1.  The excerpts from its 
content were copied from the data generated by the 
insulin pump used in our experiment.  These pumps 
generate only a fraction of the data needed for the 
APData model and therefore all subjective and non-
clinical data were collected/inserted through user 
input.  We had the data for 24-hour time/stamp and the 
field(s), in which we had no available data, were left 
empty. 
After uploading the APData into WA we ran 
numerous experiments and explored all possible 
options given by WA to define trends and insights on 
the data stored in APData.  Initially, we did not wish 
to create any particular question to which we may have 
wanted to obtain the answer using WA.   The purpose 
was to find out and assess the value of data analytics 
offered by WA.  Due to space restriction, we cannot 
show the scale of our experiments and results, but 
would mention results, which surprised us. 
Naturally, we were interested to see weather WA 
would define main “drivers” for the BG data and their 
strengths.  This would give us an indication of whether 
there were any co-relations between data stored in 
different columns of Table 1.  We were not interested 
in results of specific calculations relevant to insulin 
administration.  We wanted to know how WA would 
manipulate the semantics of data stored outside the left 
column. Figure 4 shows the main drivers for current 
BG levels and their strengths and places “Current 
Activity”, “Location” and “Body Temperature” as 
drivers of 58%, 57% and 53% strength respectively.  
Figure 5 shows the contribution of BG current over 
TIME and CURRENT ACTIVITY and shows which 
activities impact current BG levels: from child care, 
cleaning/cooking, to sleeping/Watching TV! 
WA also allowed creating our questions and 
provided the starting point for exploring the content of 
APData further.  The use of WA proved to be user 
friendly and did not require special technical skills for 
running the experiments. Therefore, it can be used for 
long-term analysis of the changes in BG levels and 
insulin administration per patient, and include the 
impact of factors outside clinical data on BG levels 
and consequently on insulin administration. 
 
Figure 5 - Contribution of BG Current 
over Time by Current Activity 
 
Figure 4 – Main Drivers for Current BG 
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6. Conclusions 
The initial motivation for this research was to 
process sensor generated data created by insulin 
pumps, using Big Data technologies.  Sensor 
generated data, continuously collected by insulin 
pumps, could be instantly processed by WA and 
advice patients on BG management on an ad-hoc 
basis.  This initial idea seemed realistic at the 
beginning of our research. 
However, after inspecting the functioning of one 
insulin pump, and looking at all visualization provided 
by the software application which supports the pump, 
it was obvious that the data collected through the 
insulin infusion system could not be processed further 
by Big Data technologies.  Furthermore, the data 
collected by current insulin infusion systems are not 
sufficient to mimic the calculations of insulin infusion 
typical for a natural pancreas.  We needed both: a new 
set of data and a new way of processing it.   
We could not find any publication that could 
address the problem of the definition of a new data set 
and its processing for an AP.  Therefore, this research 
is an attempt towards creating a full-scale software 
solution for an AP.  In computations, we have to come 
closer to the functioning of our natural organ: we 
created a new dataset in Table 1, and a new set of 
computations that share data involved in them for 
insulin administration in Figures 2 and 3.  In this paper, 
we show only one part of our implementation, which 
contained WA.  This is a suitable environment for an 
ad-hoc testing of the content of big data sets and is 
available as a free platform for academic research.  
There are two outcomes of this research. Firstly, 
we have paved a different way towards an AP because: 
 We propose a software model that utilizes three 
different types of computations. 
 The software architectural model is reusable and 
may be used for any other organ that needs 
continuous medication/treatment.  
 WA upon the new data model is efficient, but any 
other Big Data technology could do the same. Our 
model is not WA specific. 
 Software applications which compute OWL 
reasoning and SQL calculations co-exist and have 
been implemented in our previous research [23] 
 Any existing algorithm which helps in insulin 
administration can be placed either within WA 
computations or within the data management 
components of the proposed architecture [11]. 
Secondly, we wanted to draw attention of 
healthcare professionals to the fact that current pumps 
do not generate sufficient data for creating a more 
natural administration of insulin. Current software 
solutions are determined by pump manufacturers, 
which does not necessarily mean that we can use them 
outside their operating environments.  
There are two pathways from this research. 
Firstly, we need to have a dialog with medical, 
healthcare professionals and pump manufacturers and 
decide which data from Table 1 must be present in 
computations for an AP. It is important that we address 
all three columns of data from Table 1 because we 
cannot see how else we can move towards an AP if we 
do not use data essential in the functioning of a natural 
pancreas.  
Secondly, to create a full-scale application, we 
need to work with teams of healthcare professionals 
and software developers, which could determine the 
exact calculations performed by SQL persistence and 
OWL reasoning.   The reusability of the model from 
Figure 3 guarantees that we can change or improve 
these calculations and reasoning, according to the data 
we collect from new devices, whenever required.   
We believe that the data model from Table 1 and 
software architecture from Figure 3 are not difficult to 
convert into an Android App or to create a new Web 
Application run by patients.  However, without 
thinking about new types of “pumps” which collect 
different data, we would not be able to use big Data 
Technologies, Analytics, Semantics stored in OWL 
and reason upon them.   Patients would still be 
dependent on scheduled visits to their healthcare 
advisers to understand how successful their insulin 
administration is. Insulin administration will not be 
very similar to our natural organ.  
The only way forward is interdisciplinary and 
collaborative research from healthcare professionals, 
patients, sensor/pump manufacturers and software 
developers. It appears that currently this collaboration 
does not exist. 
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